<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01625169</url>
  </required_header>
  <id_info>
    <org_study_id>HS-09-00698</org_study_id>
    <nct_id>NCT01625169</nct_id>
  </id_info>
  <brief_title>Etravirine Pharmacokinetics and HIV Viral Load in Breast Milk and Plasma</brief_title>
  <official_title>Antiretroviral Drug Concentrations and HIV Viral Load in Breast Milk and Plasma in HIV+ Women Receiving HAART (Highly Active Antiretroviral Therapy) Therapy: Etravirine (ETR) Pharmacokinetics (PK) in Breast Milk and Plasma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      HIV positive pregnant women who receive potent combination antiretroviral therapy over at
      least the last trimester of pregnancy, and who have proper obstetric interventions and are
      able to avoid breast feeding, decrease the risk of having an infected infant to about 1%.
      Breast milk HIV-1 RNA (cell free) viral load is significantly associated with breast milk
      transmission, and a 2-fold increased risk of transmission associated with every 10-fold
      increase in breast milk viral load has been reported. In addition, cell associated virus (HIV
      DNA) was associated with a significant increase in risk of transmission independent of the
      level of cell-free viral RNA.

      However, multiple studies of HIV positive women giving birth have shown that exclusive
      breast-feeding carries a much lower risk of HIV transmission than mixed breast-feeding
      (defined as breast milk along with complementary food, other milk, and/or infant formula).
      The proposed study will measure the antiretroviral (ARV) drug etravirine concentrations in
      blood and breast milk in postpartum HIV positive women on HAART therapy. The short-term goal
      is to determine how much etravirine penetrates into breast milk, and whether it leads to
      undetectable HIV viral load in the breast milk and therefore has the potential to decrease
      the risk of transmission of HIV through breast milk. The long term goal is to see if breast
      milk HIV levels can be lowered sufficiently to prevent maternal to child transmission (MTCT)
      of HIV in infants receiving only breast feeding in resource poor areas.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Plasma Concentration of Etravirine in Plasma</measure>
    <time_frame>Day 5</time_frame>
    <description>Cmax ng/ml
Note: One participant did not complete the Day 5 evaluation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Concentration of Etravirine in Breast Milk</measure>
    <time_frame>day 5</time_frame>
    <description>Cmax ng/ml
Note: One participant did not complete the Day 5 evaluation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Concentration of Etravirine in Breast Milk</measure>
    <time_frame>day 14</time_frame>
    <description>Cmax ng/mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Plasma Concentration of Etravirine in Plasma</measure>
    <time_frame>day 14</time_frame>
    <description>Cmax ng/mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve (AUC) 0-12 for Plasma</measure>
    <time_frame>Day 5: 0, 2,4, 8 and 24 hours post dose</time_frame>
    <description>AUC 0-12 ng*hr/ml</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve (AUC) 0-12 for Plasma</measure>
    <time_frame>Day 14: 0, 2,4, 8 and 24 hours post dose</time_frame>
    <description>AUC 0-12 ng*hr/ml</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve (AUC) 0-12 for Breast Milk</measure>
    <time_frame>Day 5</time_frame>
    <description>AUC 0-12 ng*hr/ml</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve (AUC) 0-12 for Breast Milk</measure>
    <time_frame>Day 14</time_frame>
    <description>AUC 0-12 ng*hr/ml</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HIV Viral Load in Breast Milk and Plasma</measure>
    <time_frame>Day 5</time_frame>
    <description>Positive HIV RNA in breast milk and plasma- LDL 40 copies/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV Viral Load in Breast Milk and Plasma</measure>
    <time_frame>Day 14</time_frame>
    <description>Positive HIV RNA in breast milk and plasma- LDL 40 copies/ml</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>HIV + pregnant women</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Etravirine pharmacokinetics in breast milk and plasma. Etravirine 200mg PO BID for 14 days with PK on days 5 and 14</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etravirine pharmacokinetics in breast milk and plasma</intervention_name>
    <description>HIV+ pregnant women will receive etravirine 200mg PO BID for 14 days postpartum. PK will be done on postpartum days 5 and 14.</description>
    <arm_group_label>HIV + pregnant women</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HIV+ pregnant women on HAART for the prevention of MTCT w/ undetectable viral load at
             time of delivery (w/i 30 days of delivery).

          2. 18 years and older

          3. Only women who are deemed by the physician as being capable of understanding that HIV
             positive women should not breastfeed will be approached.

          4. Life expectancy greater than 6 months

          5. No known allergies to etravirine

          6. Willingness of subject to adhere to protocol requirements.

        Exclusion Criteria:

          1. Pregnant women with medical or psychological contraindications to breast milk
             expression.

          2. Requirements for prohibited medications:

               -  ARV: Tipranavir/ritonavir, fosamprenavir/ritonavir, atazanavir/ritonavir, and
                  protease inhibitors administered without ritonavir, nonnucleoside reverse
                  transcriptase inhibitor (NNRTIs).

               -  Alternative/CAM: St. John's wort

               -  Anticonvulsants: Phenobarbital, carbamazepine , phenytoin

               -  Anti-infectives: Rifampin
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LaShonda Y Spencer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LAC+USC MCA Clinic</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2012</study_first_submitted>
  <study_first_submitted_qc>June 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2012</study_first_posted>
  <results_first_submitted>June 9, 2014</results_first_submitted>
  <results_first_submitted_qc>July 14, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 7, 2014</results_first_posted>
  <last_update_submitted>August 11, 2014</last_update_submitted>
  <last_update_submitted_qc>August 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern California</investigator_affiliation>
    <investigator_full_name>LaShonda</investigator_full_name>
    <investigator_title>Assistant Prof of Clinical Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>HIV</keyword>
  <keyword>Breast milk</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etravirine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>HIV + Pregnant Women</title>
          <description>Etravirine PK on days 5 and 14
Etravirine pharmacokinetics in breast milk and plasma: HIV+ pregnant women will receive etravirine for 14 days postpartum. PK will be done on postpartum days 5 and 14.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>HIV + Pregnant Women</title>
          <description>Etravirine PK on days 5 and 14
Etravirine pharmacokinetics in breast milk and plasma: HIV+ pregnant women will receive etravirine for 14 days postpartum. PK will be done on postpartum days 5 and 14.
There is only one arm- all pregnant women enrolled into the study will receive Etravirine 200mg PO bid for 14 days postpartum</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.1" lower_limit="21" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Pregnancies</title>
          <units>pregnancies</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Gravida</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3" lower_limit="1" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2" lower_limit="0" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abortion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type of Delivery</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>C-section</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaginal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Timing of Delivery</title>
          <units>number participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Term</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Preterm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Breast Feeding</title>
          <description>Data only available for 8 participants.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Absolute CD4 at Delivery</title>
          <units>cells/ml</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="437" lower_limit="157" upper_limit="913"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Peak Plasma Concentration of Etravirine in Plasma</title>
        <description>Cmax ng/ml
Note: One participant did not complete the Day 5 evaluation.</description>
        <time_frame>Day 5</time_frame>
        <population>Note: One participant did not complete the Day 5 evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV + Pregnant Women</title>
            <description>Etravirine PK on days 5 and 14
Etravirine pharmacokinetics in breast milk and plasma: HIV+ pregnant women will receive etravirine for 14 days postpartum. PK will be done on postpartum days 5 and 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Plasma Concentration of Etravirine in Plasma</title>
          <description>Cmax ng/ml
Note: One participant did not complete the Day 5 evaluation.</description>
          <population>Note: One participant did not complete the Day 5 evaluation.</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="497.6" spread="261.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Peak Concentration of Etravirine in Breast Milk</title>
        <description>Cmax ng/ml
Note: One participant did not complete the Day 5 evaluation.</description>
        <time_frame>day 5</time_frame>
        <population>Note: One participant did not complete the Day 5 evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV + Pregnant Women</title>
            <description>Etravirine PK on days 5 and 14
Etravirine pharmacokinetics in breast milk and plasma: HIV+ pregnant women will receive etravirine for 14 days postpartum. PK will be done on postpartum days 5 and 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Concentration of Etravirine in Breast Milk</title>
          <description>Cmax ng/ml
Note: One participant did not complete the Day 5 evaluation.</description>
          <population>Note: One participant did not complete the Day 5 evaluation.</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="685.4" spread="477.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Peak Concentration of Etravirine in Breast Milk</title>
        <description>Cmax ng/mL</description>
        <time_frame>day 14</time_frame>
        <population>Note: One participant did not complete the Day 14 evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV + Pregnant Women</title>
            <description>Etravirine PK on days 5 and 14
Etravirine pharmacokinetics in breast milk and plasma: HIV+ pregnant women will receive etravirine for 14 days postpartum. PK will be done on postpartum days 5 and 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Concentration of Etravirine in Breast Milk</title>
          <description>Cmax ng/mL</description>
          <population>Note: One participant did not complete the Day 14 evaluation.</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1805.4" spread="1390.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Peak Plasma Concentration of Etravirine in Plasma</title>
        <description>Cmax ng/mL</description>
        <time_frame>day 14</time_frame>
        <population>Note: One participant did not complete the Day 14 evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV + Pregnant Women</title>
            <description>Etravirine PK on days 5 and 14
Etravirine pharmacokinetics in breast milk and plasma: HIV+ pregnant women will receive etravirine for 14 days postpartum. PK will be done on postpartum days 5 and 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Plasma Concentration of Etravirine in Plasma</title>
          <description>Cmax ng/mL</description>
          <population>Note: One participant did not complete the Day 14 evaluation.</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="564.6" spread="412.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve (AUC) 0-12 for Plasma</title>
        <description>AUC 0-12 ng*hr/ml</description>
        <time_frame>Day 5: 0, 2,4, 8 and 24 hours post dose</time_frame>
        <population>One participant did not complete Day 5 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV + Pregnant Women</title>
            <description>Etravirine PK on days 5 and 14
Etravirine pharmacokinetics in breast milk and plasma: HIV+ pregnant women will receive etravirine for 14 days postpartum. PK will be done on postpartum days 5 and 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) 0-12 for Plasma</title>
          <description>AUC 0-12 ng*hr/ml</description>
          <population>One participant did not complete Day 5 visit.</population>
          <units>ng*hr/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3622.1" spread="2020.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve (AUC) 0-12 for Plasma</title>
        <description>AUC 0-12 ng*hr/ml</description>
        <time_frame>Day 14: 0, 2,4, 8 and 24 hours post dose</time_frame>
        <population>One participant did not complete D14 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV + Pregnant Women</title>
            <description>Etravirine PK on days 5 and 14
Etravirine pharmacokinetics in breast milk and plasma: HIV+ pregnant women will receive etravirine for 14 days postpartum. PK will be done on postpartum days 5 and 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) 0-12 for Plasma</title>
          <description>AUC 0-12 ng*hr/ml</description>
          <population>One participant did not complete D14 visit.</population>
          <units>ng*hr/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4096" spread="2999.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve (AUC) 0-12 for Breast Milk</title>
        <description>AUC 0-12 ng*hr/ml</description>
        <time_frame>Day 5</time_frame>
        <population>One participant did not complete D5 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV + Pregnant Women</title>
            <description>Etravirine PK on days 5 and 14
Etravirine pharmacokinetics in breast milk and plasma: HIV+ pregnant women will receive etravirine for 14 days postpartum. PK will be done on postpartum days 5 and 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) 0-12 for Breast Milk</title>
          <description>AUC 0-12 ng*hr/ml</description>
          <population>One participant did not complete D5 visit.</population>
          <units>ng*hr/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4371.9" spread="3491.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve (AUC) 0-12 for Breast Milk</title>
        <description>AUC 0-12 ng*hr/ml</description>
        <time_frame>Day 14</time_frame>
        <population>One participant did not complete D14 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV + Pregnant Women</title>
            <description>Etravirine PK on days 5 and 14
Etravirine pharmacokinetics in breast milk and plasma: HIV+ pregnant women will receive etravirine for 14 days postpartum. PK will be done on postpartum days 5 and 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) 0-12 for Breast Milk</title>
          <description>AUC 0-12 ng*hr/ml</description>
          <population>One participant did not complete D14 visit.</population>
          <units>ng*hr/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12953.7" spread="10200.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HIV Viral Load in Breast Milk and Plasma</title>
        <description>Positive HIV RNA in breast milk and plasma- LDL 40 copies/ml</description>
        <time_frame>Day 5</time_frame>
        <population>One participant did not complete Visit D5.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV + Pregnant Women</title>
            <description>Etravirine PK on days 5 and 14
Etravirine pharmacokinetics in breast milk and plasma: HIV+ pregnant women will receive etravirine for 14 days postpartum. PK will be done on postpartum days 5 and 14.</description>
          </group>
        </group_list>
        <measure>
          <title>HIV Viral Load in Breast Milk and Plasma</title>
          <description>Positive HIV RNA in breast milk and plasma- LDL 40 copies/ml</description>
          <population>One participant did not complete Visit D5.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Breast milk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HIV Viral Load in Breast Milk and Plasma</title>
        <description>Positive HIV RNA in breast milk and plasma- LDL 40 copies/ml</description>
        <time_frame>Day 14</time_frame>
        <population>One participant did not complete D14 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV + Pregnant Women</title>
            <description>Etravirine PK on days 5 and 14
Etravirine pharmacokinetics in breast milk and plasma: HIV+ pregnant women will receive etravirine for 14 days postpartum. PK will be done on postpartum days 5 and 14.</description>
          </group>
        </group_list>
        <measure>
          <title>HIV Viral Load in Breast Milk and Plasma</title>
          <description>Positive HIV RNA in breast milk and plasma- LDL 40 copies/ml</description>
          <population>One participant did not complete D14 visit.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Breast milk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Event reporting was collecting during the study and up through the last study visit.</time_frame>
      <desc>There were no significant toxicities or adverse events attributable to Etravirine administration in any of the subjects who received study drug. Safety labs were obtained at D14 visit. No lab toxicities were observed.</desc>
      <group_list>
        <group group_id="E1">
          <title>HIV + Pregnant Women</title>
          <description>Etravirine PK on days 5 and 14
Etravirine pharmacokinetics in breast milk and plasma: HIV+ pregnant women will receive etravirine for 14 days postpartum. PK will be done on postpartum days 5 and 14.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>One patient out of 9 (11%) reported diarrhea at the D5 PK visit.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>1 of 9 (11%) reported a self-resolving headache on D14; not likely to be related to ETR.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Breast Tenderness</sub_title>
                <description>66% of the subjects complained of breast tenderness related to pumping.</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>LaShonda Spencer</name_or_title>
      <organization>USC</organization>
      <phone>323 226-6437</phone>
      <email>lspencer@usc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

